Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05203328 · ClinicalTrials.gov registry record · NA
Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care During EBUS Bronchoscopy
A NA study of Lung Cancer, sponsored by The Cooper Health System.
- Recruiting
- Registry status
- NA
- Development phase
- 198
- Enrollment target
- 1
- Study location
NCT05203328: Recruiting NA study of Lung Cancer, sponsored by The Cooper Health System.
NCT05203328 is a NA study of Lung Cancer that is actively recruiting participants, run by The Cooper Health System. The registered enrollment target is 198 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05203328, a NA study of Lung Cancer, is actively recruiting participants, sponsored by The Cooper Health System.
- RECRUITING
- Registry status
- NA
- Development phase
- 198 participants
- Enrollment target
- 1
- Study location
Study Summary
Our objective is to assess whether the use of high flow nasal cannula (Vapotherm, Exeter, NH) with monitored anesthesia care (MAC) during an endobronchial ultrasound (EBUS) bronchoscopy procedure will lead to less procedure interruptions, less hypoxic episodes, shorter duration of hypoxic episodes and shorter procedural durations when compared to regular MAC using a regular nasal canula.
Primary Outcome
We will count the number of interruptions during EBUS procedure for hypoxia
Conditions Studied
Interventions
- DEVICE Vapotherm
- DEVICE Regular nasal canula
Study Locations (1)
New Jersey
- Cooper University Hospital - Camden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 198 participants |
| Start Date | 2022-02-01 |
| Est. Completion | 2026-05 |
| Phase | NA |
What NCT05203328 shows while recruiting
NCT05203328 is an interventional study that assigns participants to a tested intervention. The registered 198 participants enrollment target is mid-sized for trials with a published cap, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Vapotherm is the first listed.
NCT05203328 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT05203328 about?
NCT05203328 is a clinical study titled "Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care During EBUS Bronchoscopy". Our objective is to assess whether the use of high flow nasal cannula (Vapotherm, Exeter, NH) with monitored anesthesia care (MAC) during an endobronchial ultrasound (EBUS) bronchoscopy procedure will lead to less procedure interruptions, less hypoxic episodes, shorter duration of hypoxic episodes a...
What is the current status of trial NCT05203328?
This trial is currently recruiting. It is a NA study. The enrollment target is 198 participants. The study started on 2022-02-01. Estimated completion is 2026-05.
What conditions does trial NCT05203328 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT05203328?
The interventions under investigation include: Vapotherm (DEVICE), Regular nasal canula (DEVICE).
Who is sponsoring clinical trial NCT05203328?
This trial is sponsored by The Cooper Health System, which has 39 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05203328 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05203328's enrollment target sits among peer trials
198 134th of 409 higher than 276 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
-
Lung Cancer Screening in High-risk Black Individuals
RECRUITING · NA
-
A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening
RECRUITING · NA
-
Exercise as Maintenance Therapy in Advanced Lung Cancer
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
Stereotactic Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05426967 · 198 participants · NA
rTMS for Military TBI-related Depression
- NCT05561114 · 198 participants · Phase 3
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus
- NCT05585190 · 198 participants · NA
Stand Up for Your Health with a Sit-stand Desk
- NCT05629494 · 198 participants · Phase 4
Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI